Novartis AG logo

NOVN - Novartis AG Share Price

CHF92.89 0.2  0.2%

Last Trade - 4:30pm

Sector
Healthcare
Size
Large Cap
Market Cap £166.76bn
Enterprise Value £183.27bn
Revenue £38.11bn
Position in Universe 5th / 1048
Bullish
Bearish
Unlock NOVN Revenue
Momentum
Relative Strength (%)
1m
3m
6m
1yr
Volume Change (%)
10d / 3m
Price vs... (%)
52w High
50d MA
200d MA
Margin of Safety
Qualifying GuruScreens
Health Trend(F-Score)
0 1 2 3 4 5 6 7 8 9
Bankruptcy Score(Z-Score)
Distress
Cautious
Safe
Earnings Manipulation Risk(M-Score)
Other Ratios
Recent History
Latest interim period vs. prior period Industry Market
3yr Compound Annual Growth Rate Industry Market
Graphical History

Revenue

NOVN Revenue Unlock NOVN Revenue

Net Income

NOVN Net Income Unlock NOVN Revenue

Normalised EPS

NOVN Normalised EPS Unlock NOVN Revenue

PE Ratio Range

NOVN PE Ratio Range Unlock NOVN Revenue

Dividend Yield Range

NOVN Dividend Yield Range Unlock NOVN Revenue
Analyst Forecasts
Price Target:
( below Price)
31st Dec 2020
31st Dec 2021
Est. Long Term Growth Rate: Net Profit
()
EPS
()
DPS
()
Net Profit
()
EPS
()
DPS
()
Consensus Estimate
1m Change
3m Change
Analyst Consensus
Strong Sell Sell Hold Buy Strong Buy
EPS 2019 /  2020
NOVN EPS Forecasts Unlock NOVN Revenue
Profile Summary

Novartis AG is a holding company, which provides healthcare solutions. The Company is engaged in the research, development, manufacturing and marketing of a range of healthcare products led by pharmaceuticals. The Company's segments include Innovative Medicines, Sandoz, Alcon and Corporate activities. Innovative Medicines researches, develops, manufactures, distributes and sells patented prescription medicines to develop health outcomes for patients and healthcare providers. Sandoz develops, manufactures, distributes and sells prescription medicines, as well as pharmaceutical active substances that are not protected by valid and enforceable third-party patents. Alcon researches, develops, manufactures, distributes and sells eye care products. Alcon is a provider of eye care with product offerings in eye care devices and vision care. The Company's range of products includes pharmaceuticals and oncology medicines, generic and biosimilar medicines, and eye care devices.

Directors
Last Annual December 31st, 2018
Last Interim September 30th, 2019
Incorporated March 1, 1996
Public Since May 7, 2001
No. of Shareholders: 162,960
No. of Employees: 109,000
Sector Healthcare
Industry Pharmaceuticals
Index FTSEurofirst 300 Pharmaceuticals & Biotechnology , FTSEurofirst 300 , FTSEurofirst 300 Ex Eurozone, FTSEurofirst 300 Ex UK, FTSE Global 100,
Exchange SIX Swiss Exchange (VTX)
Shares in Issue 2,264,608,111
Free Float (0.0%)
Eligible for
ISAs
SIPPs
NOVN Share Price Performance
Share Price
Bid - Ask
Low - High
Spread
Day's Change
Avg Volume
Open - Close
Range (12m)
Beta
Latest News for NOVN
Upcoming Events for NOVN
Wednesday 29th January, 2020
Q4 2019 Novartis AG Earnings Release
Wednesday 29th January, 2020
Q4 2019 Novartis AG Earnings Call
Friday 28th February, 2020
Novartis AG Annual Shareholders Meeting
Friday 28th February, 2020 Estimate
Novartis AG Annual Shareholders Meeting
Tuesday 28th April, 2020
Q1 2020 Novartis AG Earnings Release
Similar to NOVN
© Stockopedia 2020, Refinitiv, Share Data Services.
This site cannot substitute for professional investment advice or independent factual verification. To use it, you must accept our Terms of Use, Privacy and Disclaimer policies.